AP9400621A0 - Influenza vaccine compositions - Google Patents

Influenza vaccine compositions

Info

Publication number
AP9400621A0
AP9400621A0 AP9400621A AP9400621A AP9400621A0 AP 9400621 A0 AP9400621 A0 AP 9400621A0 AP 9400621 A AP9400621 A AP 9400621A AP 9400621 A AP9400621 A AP 9400621A AP 9400621 A0 AP9400621 A0 AP 9400621A0
Authority
AP
ARIPO
Prior art keywords
vaccine compositions
influenza vaccine
influenza
compositions
vaccine
Prior art date
Application number
AP9400621A
Other versions
AP431A (en
Original Assignee
Smithkline Beecham Coroporatio
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Coroporatio, Smithkline Beecham Biolog filed Critical Smithkline Beecham Coroporatio
Publication of AP9400621A0 publication Critical patent/AP9400621A0/en
Application granted granted Critical
Publication of AP431A publication Critical patent/AP431A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
APAP/P/1994/000621A 1993-02-19 1994-02-17 Influenza vaccine compositions. AP431A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2153593A 1993-02-19 1993-02-19
US11575093A 1993-09-01 1993-09-01

Publications (2)

Publication Number Publication Date
AP9400621A0 true AP9400621A0 (en) 1994-04-30
AP431A AP431A (en) 1995-11-15

Family

ID=26694802

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1994/000621A AP431A (en) 1993-02-19 1994-02-17 Influenza vaccine compositions.

Country Status (9)

Country Link
EP (1) EP0684838A1 (en)
AP (1) AP431A (en)
AU (1) AU6141094A (en)
CA (1) CA2156525A1 (en)
IL (1) IL108681A0 (en)
MA (1) MA23118A1 (en)
MX (1) MX9401225A (en)
SI (1) SI9400085A (en)
WO (1) WO1994019013A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
ATE157882T1 (en) * 1993-03-23 1997-09-15 Smithkline Beecham Biolog VACCINE COMPOSITIONS CONTAINING 3-0-DEAZYLATED MONOPHOSPHORYL LIPID A
UA56132C2 (en) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6261573B1 (en) * 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
AT407958B (en) * 1999-02-11 2001-07-25 Immuno Ag INACTIVATED INFLUENZA VIRUS VACCINE FOR NASAL OR ORAL APPLICATION
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
RU2164148C1 (en) * 2000-08-09 2001-03-20 Петров Рэм Викторович Vaccine against influenza virus and method of its preparing
ATE503493T1 (en) * 2001-02-23 2011-04-15 Glaxosmithkline Biolog Sa INFLUENZA VACCINE COMPOSITIONS FOR INTRADERMAL ADMINISTRATION
JP2004536785A (en) * 2001-02-23 2004-12-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム New vaccine
DE10293048T1 (en) * 2001-04-27 2003-07-31 Glaxosmithkline Biolog Sa New vaccine
JP2008512443A (en) 2004-09-09 2008-04-24 カイロン ベーリング ゲーエムベーハー アンド カンパニー Reduce potential iatrogenic risk associated with influenza vaccines
EP2923711A1 (en) 2004-11-03 2015-09-30 Novartis Vaccines and Diagnostics, Inc. Influenza vaccination
PT1861120T (en) 2005-03-23 2016-08-18 Glaxosmithkline Biologicals Sa Use of an influenza virus and an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
HRP20140488T1 (en) 2006-07-17 2014-07-04 Glaxosmithkline Biologicals S.A. Influenza vaccine
BRPI0721393B8 (en) * 2007-03-22 2022-09-06 Fund Butantan method to obtain monophosphorylated lipid from bordetella pertussis as a by-product of cellular pertussis vaccine production
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
WO2009115917A2 (en) 2008-03-18 2009-09-24 Novartis Ag Improvements in preparation of influenza virus vaccine antigens
US9657359B2 (en) 2010-09-07 2017-05-23 Novartis Ag Generic assays for detection of mamalian reovirus
EP2653156A1 (en) * 2012-10-01 2013-10-23 College of Pharmacy of Taif University Pharmaceutical emulsion composition and use thereof
CN106535929A (en) * 2014-03-25 2017-03-22 美国政府陆军部 Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines
KR20250078621A (en) 2018-07-10 2025-06-02 세퀴러스 피티와이 리미티드 Removal of agglomerates
CN112361796A (en) * 2020-11-13 2021-02-12 安徽省天长市周氏羊业有限公司 Crushing and drying device used before straw recovery and storage
CN114989269B (en) * 2022-06-30 2023-09-19 天康制药股份有限公司 Bovine akabane immunogenicity antigen and vaccine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5230899A (en) * 1985-08-07 1993-07-27 Smithkline Beecham Corporation Methods and compositions for making liposomes
IL79114A (en) * 1985-08-07 1990-09-17 Allergan Pharma Method and composition for making liposomes
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ241926A (en) * 1988-08-25 1993-08-26 Liposome Co Inc Immunisation dosage form comprising a salt of an organic acid derivative of a sterol and an antigen
DK425789A (en) * 1988-08-31 1990-03-01 Smithkline Beecham Corp VACCINAL POLYPEPTIDES
AU640348B2 (en) * 1988-08-31 1993-08-26 Smithkline Beecham Corporation Vaccinal Polypeptides
JPH06501151A (en) * 1990-09-28 1994-02-10 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） Vaccines based on gp160 or its derivatives containing derivatives of gp160 and adjuvants
EP0563091A1 (en) * 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines based on hepatitis b surface antigen
FR2671974A1 (en) * 1991-01-24 1992-07-31 Pasteur Merieux Serums Vacc INFLUENZA VACCINE COMPOSITION WITH SYNERGISTIC EFFECT, CONTAINING AS AN ADDITIVE TO INFLUENZA VIRUS CORE.
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
DK0671948T3 (en) * 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccine containing adjuvants

Also Published As

Publication number Publication date
AU6141094A (en) 1994-09-14
MA23118A1 (en) 1994-10-01
WO1994019013A1 (en) 1994-09-01
MX9401225A (en) 1994-08-31
EP0684838A1 (en) 1995-12-06
SI9400085A (en) 1994-09-30
IL108681A0 (en) 1994-05-30
AP431A (en) 1995-11-15
CA2156525A1 (en) 1994-09-01

Similar Documents

Publication Publication Date Title
IL109056A0 (en) Vaccine compositions
IL108681A0 (en) Influenza vaccine compositions
IL105161A0 (en) Vaccine compositions
IL118004A0 (en) Vaccine compositions
ZA961460B (en) Vaccine compositions
AU1308495A (en) Influenza vaccine
IL108915A0 (en) Polynucleotide vaccine against influenza virus
GR3034798T3 (en) Influenza vaccine
ZA946262B (en) Pharmaceutical compositions
AP9901448A0 (en) Vaccine composition against malaria
GB9401787D0 (en) Vaccine compositions
IL110201A0 (en) Novel pharmaceutical compositions
GB9317610D0 (en) Pharmaceutical compositions
GB9326425D0 (en) Vaccine compositions
GB9317504D0 (en) Pharmaceutical compositions
GB9614618D0 (en) Vaccine compositions
HU9401771D0 (en) Pharmaceutical compositions cintaining ipsapiron
GB9320454D0 (en) Vaccine compositions
ZA941957B (en) Vaccine compositions
GB9403417D0 (en) Vaccine compositions
GB9416097D0 (en) Vaccine compositions
GB9425980D0 (en) Vaccine compositions
GB9601739D0 (en) Vaccine Compositions
ZA949128B (en) Vaccine
IL94510A0 (en) Influenza vaccine